Alterity Therapeutics Limited, (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) will present clinical data from its lead drug candidate PBT434 at the American Academy of Neurology Annual Meeting in Philadelphia, USA, from 5-9th May 2019. Alterity will feature prominently at the Annual Meeting with a Platform Presentation on Sunday 5thMay featuring data from the company’s ...
Category: Investor Announcement
Alterity Therapeutics Investor Presentation 10 April 2019
Alterity Therapeutics Limited, (formerly Prana Biotechnology Limited) is meeting this week with sophisticated investors in both Singapore and Hong Kong in the first leg of a global investor roadshow.
We wish to announce the Company name change has been processed by the Australian Securities and Investment Commission and the Company has changed its name from “Prana Biotechnology Limited” to “Alterity Therapeutics Limited”.
Alterity Therapeutics Limited (formerly Prana Biotechnology Limited) (ASX:PBT) (“Alterity” or “the Company”) is pleased to announce completion of the strategic investment by Life Biosciences LLC (Life) of an initial US$7.5m (A$10.526m at an exchange rate of A$1.00 to US$0.7125) in the Company (Subscription).
The Company wishes to advise that all resolutions contained in the Notice of Meeting were carried on a show of hands.
Prana Biotechnology today advises that a conference call facility will be available at the Extraordinary General Meeting (EGM) scheduled for Friday, April 5, 2019, at 11:00 AM AEDT.
Prana has today announced that is has received a A$3.3 million cash refund under the Australian Government’s R&D Tax Incentive Scheme.
Notice of General Meeting 2019
Prana receives first orphan drug designation from the FDA for the treatment of Multiple System Atrophy